Pre-screening for peptide sensitivities and maintaining emergency response capabilities are standard practices in professional research settings
These studies are conducted strictly for educational and exploratory purposes and are not positioned as peptide therapy
Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback
Smell test Normal: Faint medicinal smell or no smell at all
They are often included as part of a broader wellness or pain management plan, especially for patients dealing with chronic conditions, inflammation, or nerve irritation
(Long-term storage at 20C is standard practice.) Reconstituted solution: 2 to 8C, used within 14 to 30 days
